Systematic Review on Association of Various Disease with Covid-19

Jay Prakash; Shivani Lodha

doi:10.55544/jrasb.3.3.16

Authors

Jay Prakash Faculty of Pharmacy, Uttarakhand Technical University Campus, Dehradun, INDIA.
Shivani Lodha Assistant Professor, Faculty of Pharmacy Uttarakhand Technical University Campus, Dehradun, INDIA.

DOI:

https://doi.org/10.55544/jrasb.3.3.16

Keywords:

COVID-19, Cardiovascular disorder, Diabetes mellitus, Hypertension, Neurological disorder

Abstract

The SARS-CoV-2 virus, which causes COVID-19, initially emerged in Wuhan City, Hubei Province, China, in early December 2019. On January 30, 2020, the World Health Organisation proclaimed the pandemic a Public Health Emergency of International Concern. There have been 49,053 confirmed cases and 1,381 fatalities globally as of February 14, 2020. The risk of developing severe COVID-19 is increased in some congenital disorders, according to reported studies, because these conditions often come with pre-existing co-morbidities that impact the circulatory and respiratory systems, leading to potentially life-threatening pneumonia. A high risk for severe COVID-19 infection is not associated with congenital disorders other than those listed, even though they cause psychological discomfort in patients. A higher risk of developing new-onset diabetes among survivors was associated with COVID-19, according to this review. Glucose dysregulation must be closely monitored throughout the recovery process from SARS-CoV-2 infection. The SARS-CoV-2 virus has unleashed a COVID-19 pandemic that rivals the size of the 1918 flu pandemic. Although respiratory symptoms predominate, neurological symptoms are also being more acknowledged as a possible clinical manifestation. It is expected that SARS-CoV-2 will create many issues impacting the central nervous system or peripheral nervous system, based on what is known about previous coronaviruses like the ones that caused SARS and the Middle East respiratory syndrome outbreaks. Diabetes mellitus and arterial hypertension are risk factors for cardiovascular disease; the impact of COVID-19 on these conditions may not be fully recognised. Recent research suggests that a family history of COVID-19 infection may raise the risk of various cardiovascular diseases to a level comparable to those of established risk factors for this condition. Furthermore, the risk of developing CVD and the severity of its symptoms are both increased in patients with a preexisting condition, such as myocarditis, acute coronary syndrome, heart failure (HF), thromboembolic consequences, or arrhythmias. Direct viral penetration into cardiovascular tissue and activation of a robust systemic inflammatory response are two hypothesised methods by which COVID-19 may influence CVD and CV risk.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., ... & Hao, P. (2020). Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences, 63, 457-460.

Farnoosh, G., Alishiri, G., Zijoud, S. H., Dorostkar, R., & Farahani, A. J. (2020). Understanding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19) based on available evidence-a narrative review. Journal of military medicine, 22(1), 1-11.

Chan, J. F. W., To, K. K. W., Chen, H., & Yuen, K. Y. (2015). Cross-species transmission and emergence of novel viruses from birds. Current opinion in virology, 10, 63-69.

He, J., Tao, H., Yan, Y., Huang, S. Y., & Xiao, Y. (2020). Molecular mechanism of evolution and human infection with SARS-CoV-2. Viruses, 12(4), 428.

Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Zhong, N. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18), 1708-1720.

Heymann, D. L. (2020). Data sharing and outbreaks: best practice exemplified. The Lancet, 395(10223), 469-470.

Liu, X., & Wang, X. J. (2020). Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. Journal of Genetics and Genomics, 47(2), 119.

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science, 367(6485), 1444-1448.

Richman, D. D., Whitley, R. J., & Hayden, F. G. (Eds.). (2020). Clinical virology. John Wiley & Sons.

Chan‐Yeung, M., & Xu, R. H. (2003). SARS: epidemiology. Respirology, 8, S9-S14.

Ralph, R., Lew, J., Zeng, T., Francis, M., Xue, B., Roux, M., ... & Kelvin, A. A. (2020). 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness. The Journal of Infection in Developing Countries, 14(01), 3-17.

Chan, J. F. W., Yuan, S., Kok, K. H., To, K. K. W., Chu, H., Yang, J., ... & Yuen, K. Y. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The lancet, 395(10223), 514-523.

Faridi, S., Niazi, S., Sadeghi, K., Naddafi, K., Yavarian, J., Shamsipour, M., ... & MokhtariAzad, T. (2020). A field indoor air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran. Science of the Total Environment, 725, 138401.

Wong, S. C. Y., Kwong, R. S., Wu, T. C., Chan, J. W. M., Chu, M. Y., Lee, S. Y., ... & Lung, D. C. (2020). Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong. Journal of Hospital Infection, 105(2), 119-127.

Hu, B., Guo, H., Zhou, P., & Shi, Z. L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 19(3), 141-154.

Khan, M. S. I., Nabeka, H., Akbar, S. M. F., Al Mahtab, M., Shimokawa, T., Islam, F., & Matsuda, S. (2020). Risk of congenital birth defects during COVID-19 pandemic: draw attention to the physicians and policymakers. Journal of global health, 10(2).

Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P. A., Cuapio, A., & Villapol, S. (2021). More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific reports, 11(1), 16144.

Schwerzmann, M., Ruperti-Repilado, F. J., Baumgartner, H., Bouma, B., Bouchardy, J., Budts, W., ... & Greutmann, M. (2021). Clinical outcome of COVID-19 in patients with adult congenital heart disease. Heart.

Barh, D., Tiwari, S., Andrade, B. S., Weener, M. E., Goes-Neto, A., Azevedo, V., ... & Ganguly, N. K. (2021). A novel multi-omics-based highly accurate prediction of symptoms, comorbid conditions, and possible long-term complications of COVID-19. Molecular omics, 17(2), 317-337.

Galloway, J. B., Norton, S., Barker, R. D., Brookes, A., Carey, I., Clarke, B. D., ... & Cantle, F. (2020). A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study. Journal of Infection, 81(2), 282-288.

Lewis, M. J., Anderson, B. R., Fremed, M., Argenio, M., Krishnan, U., Weller, R., ... & Rosenbaum, M. (2020). Impact of coronavirus disease 2019 (COVID‐19) on patients with congenital heart disease across the lifespan: the experience of an academic congenital heart disease center in New York city. Journal of the American Heart Association, 9(23), e017580.

Baumgartner, H., Budts, W., Chessa, M., Deanfield, J., Eicken, A., Holm, J., ... & Working Group on Grown-up Congenital Heart Disease of the European Society of Cardiology. (2014). Recommendations for organization of care for adults with congenital heart disease and for training in the subspecialty of ‘Grown-up Congenital Heart Disease’in Europe: a position paper of the Working Group on Grown-up Congenital Heart Disease of the European Society of Cardiology. European heart journal, 35(11), 686-690.

Guzik, T. J., Mohiddin, S. A., Dimarco, A., Patel, V., Savvatis, K., Marelli-Berg, F. M., ... & McInnes, I. B. (2020). COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular research, 116(10), 1666-1687.

Tan, W., & Aboulhosn, J. (2020). The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. International journal of cardiology, 309, 70-77.

John Hopkins University. (2021). John Hopkins University & Medicine: Coronavirus Resource Center.

Cheng, S., Zhao, Y., Wang, F., Chen, Y., Kaminga, A. C., & Xu, H. (2021). Comorbidities’ potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis. Medicine, 100(12), e24971.

Mitrani, R. D., Dabas, N., & Goldberger, J. J. (2020). COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart rhythm, 17(11), 1984-1990.

Writing Committee, Gluckman, T. J., Bhave, N. M., Allen, L. A., Chung, E. H., Spatz, E. S., ... & Verma, A. K. (2022). 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 79(17), 1717-1756.

Lim, S., Bae, J. H., Kwon, H. S., & Nauck, M. A. (2021). COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews Endocrinology, 17(1), 11-30.

Ceriello, A. (2020). Hyperglycemia and COVID-19: What was known and what is really new?. Diabetes research and clinical practice, 167, 108383.

Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Canadian Journal of Cardiology, 34(5), 575-584.

Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation research, 107(9), 1058-1070.

Berbudi, A., Rahmadika, N., Tjahjadi, A. I., & Ruslami, R. (2020). Type 2 diabetes and its impact on the immune system. Current diabetes reviews, 16(5), 442-449.

Šestan, M., Marinović, S., Kavazović, I., Cekinović, Đ., Wueest, S., Wensveen, T. T., ... & Polić, B. (2018). Virus-induced interferon-γ causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity, 49(1), 164-177.

Chen, J., Wu, C., Wang, X., Yu, J., & Sun, Z. (2020). The impact of COVID-19 on blood glucose: a systematic review and meta-analysis. Frontiers in endocrinology, 11, 574541.

Brola, W., & Wilski, M. (2022). Neurological consequences of COVID-19. Pharmacological Reports, 74(6), 1208-1222.

Priyal, Sehgal, V., Kapila, S., Taneja, R., Mehmi, P., & Gulati, N. (2023). Review of Neurological Manifestations of SARS-CoV-2. Cureus, 15(4), e38194. https://doi.org/10.7759/cureus.38194

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., ... & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 395(10229), 1054-1062.

Singh, A. K., Gupta, R., & Misra, A. (2020). Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(4), 283-287.

Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., ... & Northwell COVID-19 Research Consortium. (2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama, 323(20), 2052-2059.

Yang, J. K., Lin, S. S., Ji, X. J., & Guo, L. M. (2010). Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta diabetologica, 47, 193-199.

Fadini, G. P., Morieri, M. L., Longato, E., & Avogaro, D. A. (2020). Prevalence and impact of diabetes among people infected with SARS-CoV-2. Journal of endocrinological investigation, 43, 867-869.

Xie, J., Tong, Z., Guan, X., Du, B., & Qiu, H. (2020). Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA network open, 3(4), e205619-e205619.

Kulcsar, K. A., Coleman, C. M., Beck, S. E., & Frieman, M. B. (2019). Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI insight, 4(20).

Zhu, L., She, Z. G., Cheng, X., Qin, J. J., Zhang, X. J., Cai, J., ... & Li, H. (2020). Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell metabolism, 31(6), 1068-1077.

Xia, C., Rao, X., & Zhong, J. (2017). Role of T lymphocytes in type 2 diabetes and diabetes-associated inflammation. Journal of diabetes research, 2017.

Hodgson, K., Morris, J., Bridson, T., Govan, B., Rush, C., & Ketheesan, N. (2015). Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology, 144(2), 171-185.

Van Crevel, R., Van De Vijver, S., & Moore, D. A. (2017). The global diabetes epidemic: what does it mean for infectious diseases in tropical countries?. The lancet Diabetes & endocrinology, 5(6), 457-468.

Li, J., Wang, X., Chen, J., Zhang, H., & Deng, A. (2020). Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA cardiology, 5(7), 825-830.

Guo, J., Huang, Z., Lin, L., & Lv, J. (2020). Coronavirus disease 2019 (COVID‐19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. Journal of the American Heart Association, 9(7), e016219.

Kreutz, R., Algharably, E. A. E. H., Azizi, M., Dobrowolski, P., Guzik, T., Januszewicz, A., ... & Burnier, M. (2020). Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence. Cardiovascular research, 116(10), 1688-1699.

Li, G., Hu, R., & Zhang, X. (2020). Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. Hypertension Research, 43(6), 588-590.

Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The lancet respiratory medicine, 8(4), e21.

Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., ... & Zhang, G. (2020). Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerging microbes & infections, 9(1), 757-760.